BLS targets $105M–$115M revenue in FY2027, signalling up to 55% growth
BLS Pharmaceuticals Limited (ASX: BLS) has issued full-year FY2027 revenue guidance of $105 million – $115 million, representing expected growth of approximately 42% – 55% on FY2026 revenue of $74.2 million.
The Company also provided Adjusted EBITDA margin guidance of 23% – 26% for the period. The guidance follows completion of BLS’s transformation into an international pharmaceutical manufacturer during FY2026.
For investors, the outlook signals a shift in emphasis. BLS is moving from a build-out phase toward execution and scale, with management framing FY2027 as a year focused on delivery against clearly stated financial targets.
When big ASX news breaks, our subscribers know first
The numbers behind the FY2027 guidance
The following table sets out the headline metrics underpinning the FY2027 guidance relative to the prior year.
| Metric | FY2026 Actual | FY2027 Guidance | Implied Change |
|---|---|---|---|
| Revenue | $74.2M | $105M – $115M | +42% to +55% |
| Adjusted EBITDA margin* | Not disclosed | 23% – 26% | — |
*Adjusted EBITDA is a non-IFRS measure, defined by the Company as earnings before interest, tax, depreciation, amortisation and share-based payments.
The growth drivers underpinning FY2027
BLS has identified four pillars it expects to underpin FY2027 performance.
-
Continued demand in Australia, supported by significant available manufacturing capacity across BLS’s GMP-licensed pharmaceutical operations to enable higher utilisation and scale.
-
Execution of existing international contracts, including the Company’s two-year A$50 million supply agreement with ADREXpharma in Germany.
-
The new GMP production site under construction in the Scottish Borders, expected to complete by the end of 2026, providing a platform to manufacture and supply pharmaceutical products into the UK and international markets.
-
A favourable and evolving global regulatory environment, with increasing political and regulatory acceptance of cannabis, MDMA and psilocybin-based medicines supporting the markets BLS serves.
Beyond these pillars, BLS has established commercial relationships across Europe and Latin America and secured manufacturing agreements with Aurora Cannabis and Curaleaf International.
The Cayman Chemical referral agreement extends this international reach further, channelling US and international customers seeking finished psilocybin and MDMA dosage forms directly to BLS for manufacture and supply, adding a pipeline of inbound demand on top of existing contracted revenue.
Understanding BLS’s multi-jurisdictional pharmaceutical platform
BLS operates through its wholly owned subsidiary, Breathe Life Sciences, across Australia, Japan, Scotland (UK) and Europe. The subsidiary is a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances, including medicinal cannabis, psilocybin and MDMA.
The platform spans final dose-form manufacturing, contract manufacturing, pharmaceutical distribution and the import and export of controlled substances. BLS manufactures products for third-party customers as well as for its own Dr Watson® brand portfolio, which it owns across multiple international markets.
Management has built a multi-jurisdictional licence stack and established solid foundations across several jurisdictions.
Director commentary
Managing Director and Founder Sam Watson framed FY2027 as an execution year building on the prior period’s progress.
Sam Watson, Managing Director and Founder
“FY26 demonstrated that our strategy is commercially tangible and significant. We enter FY27 with more manufacturing capacity, better market access, bigger contracts and more opportunities than ever before. We have built a multi-jurisdictional licence stack and established solid foundations. Our focus in FY27 is on execution and delivering sustained, long-term value for our shareholders.”
The investment thesis and what to watch in FY2027
The central thesis is straightforward. BLS has moved from build-out to execution, and the FY2027 revenue guidance provides shareholders with a measurable benchmark against which to assess delivery through the year.
Several catalysts and timelines warrant attention:
-
Completion of the Scottish Borders GMP site by the end of 2026, which is expected to add manufacturing capacity and broaden international market access.
-
Continued delivery against the two-year A$50 million ADREXpharma supply agreement in Germany.
-
Utilisation of the available Australian manufacturing capacity to support higher throughput and scale.
Underpinning these operational milestones is the evolving global regulatory backdrop, with expanding acceptance of cannabis, MDMA and psilocybin-based medicines supporting the markets BLS serves. With targets now stated in numbers, FY2027 shapes up as an execution year measured against a clear benchmark.
Investors exploring how BLS is expanding its Australian product portfolio alongside its international manufacturing scale-up will find our detailed coverage of the Trexapharm commercialisation agreement useful, as it walks through the TREXAVIVE partnership structure, the TGA access pathways involved, and the early clinical data underpinning the deal.
Don’t Miss the Next Healthcare Stock Breakout
Big News Blast delivers FREE breaking ASX healthcare and pharmaceutical news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 subscribers are already getting the jump on market-moving announcements. Click the “Free Alerts” button at StockWire X to stay ahead of the next big move.